Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis: American …

S MacLean, S Mulla, EA Akl, M Jankowski, PO Vandvik… - Chest, 2012 - Elsevier
Background Development of clinical practice guidelines involves making trade-offs between
desirable and undesirable consequences of alternative management strategies. Although …

Treatment of cancer-associated thrombosis

AYY Lee, EA Peterson - Blood, The Journal of the American …, 2013 - ashpublications.org
Therapeutic options for the management of venous thromboembolism (VTE) in patients with
cancer remain very limited. Although low-molecular-weight heparin monotherapy has been …

Anticoagulation of cancer patients with non‐valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH

A Delluc, TF Wang, ES Yap, C Ay… - … of thrombosis and …, 2019 - Wiley Online Library
1 BACKGROUND Atrial fibrillation is the most common cardiac arrhythmia, affecting
approximately 1.5% to 2% of the general population, increasing by a further 1.8% in the …

Does IQ explain socioeconomic inequalities in health? Evidence from a population based cohort study in the west of Scotland

GD Batty, G Der, S Macintyre, IJ Deary - Bmj, 2006 - bmj.com
Objective To test the hypothesis that IQ is a fundamental cause of socioeconomic
inequalities in health. Design Cross sectional and prospective cohort study, in which …

Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study

S Noble, H Prout, A Nelson - Patient preference and adherence, 2015 - Taylor & Francis
Introduction Thrombosis remains the most common preventable cause of mortality in cancer
patients receiving chemotherapy. Whilst the prophylaxis and treatment of this condition is …

[HTML][HTML] Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology

S Noble, A Matzdorff, A Maraveyas, MV Holm… - …, 2015 - ncbi.nlm.nih.gov
Low molecular weight heparins have demonstrated superiority over coumarins in the
extended treatment of cancer-associated thrombosis and are recommended as first-line …

[HTML][HTML] Factors influencing adherence to clinical guidelines in the management of cancer‐associated thrombosis

I Mahé, J Chidiac, H Helfer, S Noble - Journal of Thrombosis and …, 2016 - Elsevier
International academic and regulatory guidelines consistently recommend the long‐term
use of low‐molecular‐weight heparins (LMWHs) as the standard for the treatment of cancer …

Cancer and stroke: what do we know and where do we go?

R Lun, D Siegal, T Ramsay, D Dowlatshahi - Thrombosis Research, 2022 - Elsevier
Cancer is an increasingly recognized cause for ischemic stroke, with recent
acknowledgement of cancer-related stroke as an emerging stroke subtype with unique …

Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study

S Seaman, A Nelson, S Noble - Patient preference and adherence, 2014 - Taylor & Francis
Background Venous thromboembolism is a common complication of cancer and its
treatments. Treatment of cancer-associated thrombosis (CAT) differs from treatment of …

Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study

S Noble, R Lewis, J Whithers, S Lewis, P Bennett - BMJ open, 2014 - bmjopen.bmj.com
Objective To explore the psychological consequences of experiencing symptomatic
pulmonary embolism (PE). Design Qualitative interview-based study using interpretative …